TY - JOUR AU - González Astorga, B AU - Salvà Ballabrera, F AU - Aranda Aguilar, E AU - Élez Fernández, E AU - García-Alfonso, P AU - González Flores, E AU - Vera García, R AU - Fernández Montes, A AU - López Muñoz, A M AU - Salud Salvia, A PY - 2021 DO - 10.1007/s12094-021-02568-y UR - http://hdl.handle.net/10668/17231 T2 - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico AB - Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil,... LA - en KW - Aflibercept KW - BRAF KW - Colorectal cancer KW - Metastatic KW - Mutation KW - Patient profile KW - Patient selection KW - RAS KW - Treatment KW - Age Factors KW - Angiogenesis Inhibitors KW - Antineoplastic Agents, Immunological KW - Antineoplastic Combined Chemotherapy Protocols KW - Bevacizumab KW - Camptothecin KW - Clinical Trials, Phase III as Topic KW - Colorectal Neoplasms KW - Drug Substitution KW - Fluorouracil KW - Genes, ras KW - Humans KW - Leucovorin KW - Liver Neoplasms KW - Lung Neoplasms KW - Mutation KW - Neovascularization, Pathologic KW - Organoplatinum Compounds KW - Proto-Oncogene Proteins B-raf KW - Receptors, Vascular Endothelial Growth Factor KW - Recombinant Fusion Proteins KW - Vascular Endothelial Growth Factor A TI - Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. TY - research article VL - 23 ER -